Indication
Aggressive systemic mastocytosis
Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems. Read more about Aggressive systemic mastocytosis
31 drugs 28 manufacturers
Drugs that treat it
Common Aggressive systemic mastocytosis therapies.
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
IMKELDI (imatinib mesylate)
IMATINIB MESYLATE
IMATINIB MESYLATE
IMATINIB MESYLATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems.
Predominantly affecting adults, the disorder is driven in most cases by activating mutations in the *KIT* gene (commonly *KIT* D816V).
It is pathophysiologically defined by mast-cell-mediated tissue infiltration that causes clinically evident, non-hematologic organ damage—termed C-findings—such as cytopenias from bone marrow failure, hepatomegaly with liver dysfunction or ascites, portal hypertension, splenomegaly with hypersplenism, malabsorption, and osteolytic bone lesions with skeletal fractures.
Unlike other advanced mast cell disorders, it manifests severe, progressive organopathy without fulfilling the diagnostic criteria for mast cell leukemia or an associated hematologic neoplasm.
- nih.gov
Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems
- orpha.net
Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems Predominantly affecting adults, the disorder is driven in most cases by activating mutations in the *KIT* gene (commonly *KIT* D816V) It is pathophysiologically defined by mast-cell-mediated tissue infiltration that causes clinically evident, non-hematologic organ damage—term...
- mayoclinic.org
Aggressive systemic mastocytosis is a rare, severe subtype of advanced systemic mastocytosis characterized by the uncontrolled clonal proliferation and infiltration of neoplastic mast cells into extracutaneous organ systems
- aaaai.org
Predominantly affecting adults, the disorder is driven in most cases by activating mutations in the *KIT* gene (commonly *KIT* D816V)
- cancer.gov
It is pathophysiologically defined by mast-cell-mediated tissue infiltration that causes clinically evident, non-hematologic organ damage—termed C-findings—such as cytopenias from bone marrow failure, hepatomegaly with liver dysfunction or ascites, portal hypertension, splenomegaly with hypersplenism, malabsorption, and osteolytic bone lesions with skeletal fractures
- dana-farber.org
Unlike other advanced mast cell disorders, it manifests severe, progressive organopathy without fulfilling the diagnostic criteria for mast cell leukemia or an associated hematologic neoplasm
Personalize your experience
Follow Aggressive systemic mastocytosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.